Progyny price target raised to $27 from $24 at Truist

Truist analyst Jailendra Singh raised the firm’s price target on Progyny (PGNY) to $27 from $24 and keeps a Hold rating on the shares as part of a broader research note previewing Q2 results for Health Care IT / Digital Health sector names. Despite the strong YTD outperformance in shares, investor sentiment still remains relatively mixed, with the interest level from long-onlies/generalist investors seen as “relatively selective”, the analyst tells investors in a research note. HCIT space has also benefited from the lack of direct tariff exposure and other macro uncertainty as well as renewed capital market activity, the firm added.